CLINICAL_TRIALS
trial_result
· 2012-09-12
Clinical Trial Update: Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression [Phase 2]
Summary
Phase 2 clinical trial update on a single IV dose of GLYX-13 (Rapastinel) for treatment-resistant major depressive disorder; study completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Naurex, Inc, an affiliate of Allergan plc | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED